CBIIF - CB2 Insights Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1561
+0.0067 (+4.51%)
At close: 2:14PM EDT
Stock chart is not supported by your current browser
Previous Close0.1494
Open0.1650
BidN/A x N/A
AskN/A x N/A
Day's Range0.1510 - 0.1650
52 Week Range0.1052 - 0.3150
Volume8,500
Avg. Volume31,741
Market Cap11.812M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire16 hours ago

    CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

    OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing Real-World Evidence driven from the point-of-care to the medical cannabis community, announced today that it has been selected as exclusive research technology platform for the leading, and only, independent scientific body on drugs in the UK, working to provide evidence-based information on safety and efficacy within medical cannabis.  A Letter of Intent has been signed between CB2 and Drug Science. “It is not often that a drug enters the market ahead of well established, widely held consensus on the health impact related to that drug,” said David Badcock, CEO, Drug Science.  “Project TWENTY21 has been designed to remove the barriers that come with a lack of evidence-based data so that physicians can become more confident, the industry can become more informed and patients can have access where and when cannabinoid treatment is appropriate.

  • GlobeNewswire10 days ago

    CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations

    TORONTO, July 09, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIT) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the.

  • Benzinga21 days ago

    CB2 Insights Enters New Jersey Cannabis Market With NJAM Acquisition

    Cannabis company CB2 Insights Inc (OTC: CBIIF ) has acquired New Jersey Alternative Medicine, one of the state’s largest medical cannabis evaluation and education clinic groups. NJAM, which operates six clinics ...

  • GlobeNewswire24 days ago

    CB2 Insights Expands Clinical Division into New Jersey with the Asset Acquisition of New Jersey Alternative Medicine Clinics

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced it will take over patient care for one of New Jersey’s largest medical cannabis evaluation and education clinic groups on July 1, 2019.  New Jersey Alternative Medicine (“NJAM”) will transfer all patient care to CB2 Insights under a performance-based agreement.  CB2 will operate within the State of New Jersey under the Company’s Canna Care Docs brand, the largest multi-state medical cannabis clinic operator in the US. The acquisition of assets of NJAM will require no cash or stock payments upon closing.

  • GlobeNewswire25 days ago

    CB2 Insights Announces Annual General & Special Meeting of Shareholders and Corporate Update

    OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has announced the date of its first Annual General Meeting (AGM) and Special Meeting of Shareholders on June 27, 2019 at 10am EST at its head office at 5045 Orbitor Drive, Mississauga, ON. The AGM will provide an opportunity for CB2 Insights to present its shareholders, in-person, the latest updates and future growth opportunities aligned with its mission to be the largest aggregator and provider of Real World Data and Evidence (“RWD” and “RWE”) related to the safety, efficacy and effectiveness of medical cannabis and cannabis derived medications. Following a transformative year in 2018 and year-over-year and sequential growth in the first quarter of 2019, both organically and through M&A activity, the Company continues its effort to drive towards profitability.

  • GlobeNewswire2 months ago

    CB2 Insights Posts Strong Growth in Clinical Revenue and Drives Operating Efficiencies in Q1 2019

    OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the first quarter of 2019. Additional information concerning the Company, including its unaudited financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended March 31, 2019, can be found at www.sedar.com and on the Company’s website.

  • ACCESSWIRE2 months ago

    CB2 Insights to Present at the 9th Annual LD Micro Invitational in Bel-Air

    OTCQB: CBIIF) ("CB2" or the "Company"), a leading data-analytics company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that CEO Prad Sekar will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 2:20PM PST / 5:20PM EST. Mr. Sekar is also scheduled to meet with investors throughout the day on June 4. "CB2 Insights has had several transformational catalysts since attending our first LD Micro event in December 2018," said Mr. Sekar.

  • GlobeNewswire2 months ago

    CB2 Insights to Host Q12019 Earnings Call on May 31, 2019

    TORONTO, May 27, 2019 -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII; OTCQB:CBIIF), a leading provider of medical cannabis-focused Real World Evidence to the healthcare.